Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
+ U) ~8 M; G8 X7 r" q v% }& n% D: dNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 # t( { _& f$ k' E$ j0 w1 L' l
+ Author Affiliations: `+ P5 G" A+ ^' F
- C! m W* |% x( q* S; [" R1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
( N+ M# q9 L( E2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
/ ]. m' L* P8 i" \$ x: e3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
' x9 h$ m$ s2 n' `2 O4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
$ a& w1 k4 I) W4 K5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
4 `5 O8 N$ }. K; p6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan ( [, U# O" u4 f+ s5 h
7Kinki University School of Medicine, Osaka 589-8511, Japan 9 |0 |. J/ I9 D6 \( I. V
8Izumi Municipal Hospital, Osaka 594-0071, Japan
r1 s5 |- Z+ \) O E! r |$ A/ j0 j9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
[9 y4 Q* ~8 ~0 J2 I8 g. }Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 1 A% l/ Z- Q' O$ k; a6 A% Z6 m5 P5 W
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
% c& p/ h, p4 Y6 q. { P5 C. ^0 E1 _3 O
|